MedPal AI (LSE:MPAL) has begun a paid digital advertising campaign for its private weight management brand, New Health, through new.co.uk, as it seeks to expand patient acquisition and increase brand visibility within the UK’s growing private weight-loss sector. The campaign centres on GLP-1-based treatment services and comes amid rising interest in obesity therapies, highlighted by strong adoption of oral semaglutide in the United States. The company aims to establish New Health as a leading platform ahead of any potential approval of oral GLP-1 weight-loss treatments in the UK.
The group said its operational footprint, which includes NHS Distance Selling Pharmacy hubs in Runcorn and Swaffham alongside automated dispensing capabilities, positions it well to support demand for both injectable GLP-1 medications and future oral alternatives once they receive UK authorisation. MedPal believes the combination of its pharmacy infrastructure and clinical platform provides a significant advantage in a rapidly expanding market.
Management considers demand for GLP-1 therapies to be one of the most important trends in healthcare and is making early investments in marketing, brand development and operational preparedness. The company believes these efforts could strengthen its position within the private obesity and weight management market while increasing engagement with both patients and commercial partners.
More about MedPal AI Plc
MedPal AI plc is a UK-based AI-native digital health and pharmacy group developing the MedPal Health OS, a vertically integrated platform that combines AI wellness coaching, clinical services, and automated pharmacy fulfilment. Through MedPal Limited, it operates a 24/7 AI-powered pharmacy distribution centre using robotic dispensing technology to provide nationwide NHS and private prescription services with rapid delivery. The company also benefits from a partnership with Epassi UK, giving app access across a large employee network.
Leave a Reply